Skip to main content
Merck, Austrian biotech to develop undisclosed vaccine candidates

Merck and Themis Bioscience of Austria have partnered for an exclusive license agreement and a research collaboration to discover and develop unspecified vaccine candidates. Themis has completed a midstage trial for its vaccine candidate MV-CHIK, which targets chikungunya.

Full Story: